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Abstract
Cancer diagnoses which are not confirmed by pathology are often under-registered in cancer registries compared to pathol-
ogy-confirmed diagnoses. It is unknown how many patients have a non pathology-confirmed cancer diagnosis, and whether 
their characteristics and survival differ from patients with a pathology-confirmed diagnosis. Participants from the prospec-
tive population-based Rotterdam Study were followed between 1989 and 2013 for the diagnosis of cancer. Cancer diagnoses 
were classified into pathology-confirmed versus non pathology-confirmed (i.e., based on imaging or tumour markers). We 
compared participant characteristics and the distribution of cancers at different sites. Furthermore, we investigated differ-
ences in overall survival using survival curves adjusted for age and sex. During a median (interquartile range) follow-up of 
10.7 (6.3–15.9) years, 2698 out of 14,024 participants were diagnosed with cancer, of which 316 diagnoses (11.7%) were 
non pathology-confirmed. Participants with non pathology-confirmed diagnoses were older, more often women, and had a 
lower education. Most frequently non pathology-confirmed cancer sites included central nervous system (66.7%), hepato-
pancreato-biliary (44.5%), and unknown primary origin (31.2%). Survival of participants with non pathology-confirmed 
diagnoses after 1 year was lower compared to survival of participants with pathology-confirmed diagnoses (32.6% vs. 63.4%; 
risk difference of 30.8% [95% CI 25.2%; 36.2%]). Pathological confirmation of cancer is related to participant characteristics 
and cancer site. Furthermore, participants with non pathology-confirmed diagnoses have worse survival than participants 
with pathology-confirmed diagnoses. Missing data on non pathology-confirmed diagnoses may result in underestimation of 
cancer incidence and in an overestimation of survival in cancer registries, and may introduce bias in aetiological research.
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Background
With ageing populations worldwide, the incidence of can-
cer is rising. In 2018, 17 million people were diagnosed 
with cancer and 9.6 million people died from cancer [1]. 
Accurate and complete registration of incident cancers is 
pivotal for cancer statistics. However, most cancer registries 
primarily rely on pathology databases. Although this limits 
the risk of false-positive diagnoses, it may result in under-
registration of cancers that are diagnosed purely on the basis 
of other sources than pathology, such as imaging features or 
tumour markers [2, 3]. This may lead to an underestimation 
of cancer incidence and to inaccurate estimates of survival. 
Furthermore, aetiological studies often only include patients 
with a pathology-confirmed cancer diagnosis, which may 
induce bias if pathological confirmation is related to patient 
or cancer characteristics.
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article (https ://doi.org/10.1007/s1065 4-019-00592 -5) contains 
supplementary material, which is available to authorized users.
 * Rikje Ruiter 
 r.ruiter@erasmusmc.nl
1 Department of Psychosocial Research and Epidemiology, 
Netherlands Cancer Institute, Plesmanlaan 121, 
1066 CX Amsterdam, The Netherlands
2 Department of Epidemiology, Erasmus MC 
- University Medical Center Rotterdam, PO Box 2040, 
3000 CA Rotterdam, The Netherlands
3 Brain and Cognition, Department of Psychology, 
University of Amsterdam, Nieuwe Achtergracht 129B, 
1018 WT Amsterdam, The Netherlands
 K. D. van der Willik et al.
1 3
Several studies have investigated characteristics of 
patients with unstaged cancer based on the Surveillance, 
Epidemiology and End Results (SEER) database [4–6] or 
state cancer registries in the United States [7–9]. It was 
found that unstaged cancer occurs more often in patients 
with older age and in patients residing in nursing homes. 
Furthermore, unstaged cancers were often cancers with a 
poor survival such as oesophagus-, liver-, and pancreatic 
cancer [6, 10]. Missing cancer stage was explained by differ-
ent reasons such as failure of the registry system, refusal for 
diagnostic testing, or absence of therapeutic consequences 
of staging. However, tumour grade was known in the major-
ity of the unstaged cancers, which suggests that the studied 
cancer population is a combination of patients with missing 
cancer stage, but with pathological confirmation of the can-
cer, and patients with missing both cancer stage and pathol-
ogy. Therefore, the incident number of patients with a cancer 
diagnosis based on other sources than pathology and their 
characteristics remain largely unknown.
Patients with suspected cancer undergo an extensive diag-
nostic work-up that includes physical examination, labora-
tory assessments, imaging features, and pathology. In some 
patients, pathology is not included in the diagnostic work-up 
of cancer. In this study, we will refer to these cancer diagno-
ses as ‘non pathology-confirmed’ diagnoses. If pathology is 
used to confirm the cancer diagnosis, we will use the term 
‘pathology-confirmed’ diagnosis.
We hypothesized that pathology is more often omitted 
in older, vulnerable patients with impaired survival. Insight 
into the number of non pathology-confirmed cancer diag-
noses and identification of the reasons for omitting pathol-
ogy in the diagnostic work-up of cancer could stimulate and 
facilitate cancer registries and aetiological research studies 
to capture these cancer diagnoses. In the current study, we 
therefore investigated the number of participants with a non 
pathology-confirmed cancer diagnosis, their characteristics, 
and the overall and cancer-specific survival in the popula-
tion-based Rotterdam Study.
Methods
Study population
This study is embedded within the Rotterdam Study, a pro-
spective population-based cohort designed to study the 
occurrence and determinants of age-related diseases in the 
general population. The objectives and design have been 
described in detail previously [11]. In 1989, all residents 
aged ≥ 55 years of the district Ommoord in Rotterdam, 
the Netherlands, were invited to participate. This initial 
cohort comprised 7983 participants (response of 78%) and 
was extended with a second subcohort in 2000 with 3011 
participants (response of 67%) who had become 55 years 
of age or moved into the study district. In 2006, the cohort 
was further extended with 3932 participants (response of 
65%) aged ≥ 45 years. In total, the Rotterdam Study com-
prises 14,926 participants aged ≥ 45 years. The current study 
includes all participants who provided informed consent for 
follow-up data collection without a history of cancer at study 
entry (N = 14,024).
The Rotterdam Study has been approved by the Medical 
Ethics Committee of the Erasmus MC (registration num-
ber MEC 02.1015) and by the Dutch Ministry of Health, 
Welfare and Sport (Population Screening Act WBO, license 
number 1071272-159521-PG). The Rotterdam Study has 
been entered into the Netherlands National Trial Register 
(NTR; www.trial regis ter.nl) and into the WHO International 
Clinical Trials Registry Platform (ICTRP; www.who.int/
ictrp /netwo rk/prima ry/en/) under shared catalogue number 
NTR6831. All participants provided written informed con-
sent to participate in the study and to have their information 
obtained from treating physicians.
Assessment of incident cancer
Diagnosis of incident cancer was based on medical records 
of general practitioners (including hospital discharge let-
ters) and furthermore through linkage with Dutch Hospital 
Data (Landelijke Basisregistratie Ziekenhuiszorg), histology 
and cytopathology registries in the region (PALGA), and 
the Netherlands Cancer Registry. Using different sources 
of cancer diagnoses, the Rotterdam Study aims to capture 
also the non pathology-confirmed diagnoses. Incident cancer 
was defined as any primary malignant tumour, excluding 
non-melanoma skin cancer. Each primary malignant tumour 
was registered, so that participants could have been diag-
nosed with multiple cancers. Cancer diagnoses were coded 
independently by two physicians and classified according 
to the International Classification of Diseases, 10th revi-
sion (ICD-10). In case of discrepancy, consensus was sought 
through consultation with a physician specialised in internal 
medicine. Level of uncertainty of diagnosis was established 
as: certain (pathology-confirmed), probable (e.g., based on 
imaging features or elevated tumour markers without patho-
logical confirmation), and possible (e.g., based on symp-
toms and physical examination, without further analysis and 
without pathological confirmation). Date of diagnosis was 
based on date of biopsy (solid tumours), laboratory assess-
ment (haematological tumours), or—if unavailable—date 
of hospital admission or hospital discharge letter. For non 
pathology-confirmed cancers, we used the date of imaging, 
date of laboratory assessment, date of physical examination, 
or—if unavailable—the date of hospital admission or hospi-
tal discharge letter. Follow-up was completed up to January 
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1st, 2014. In case of multiple cancers within one participant, 
we only included the first diagnosis for analyses.
Assessment of mortality
Information on vital status was updated continuously. Date 
of death was obtained and verified through notification by 
the municipal administration. Cause of death was obtained 
through follow-up of records of general practitioners and 
hospital discharge letters, and was classified according to the 
ICD-10 by two research physicians independently. Thereaf-
ter, a medical expert in the field reviewed all coded events. 
Cancer-specific mortality was defined as mortality attributed 
to malignant neoplasms (ICD-10 C00-C97).
Assessment of characteristics
During home interviews at study entry, participants provided 
information on marital status, educational level, smoking 
status, and alcohol use. Marital status was categorised as 
living with or without partner. Educational level was clas-
sified into primary education, lower education (lower/inter-
mediate general education or lower vocational education), 
intermediate (intermediate vocational education or higher 
general education), or higher (higher vocational education 
or university). Smoking habits were categorised as never, 
current, or former smoker. Alcohol use was classified into 
any use or no use of alcohol. At the research centre, height 
and weight were measured from which the body mass index 
(BMI; kg/m2) was computed. Hypertension was defined as 
a resting blood pressure exceeding 140/90 mmHg or the 
use of blood pressure lowering medication [12]. Diabe-
tes was defined as use of antidiabetic medication, fasting 
serum glucose level ≥ 7.1 mmol/L, or random serum glu-
cose level ≥ 11.1 mmol/L [13]. History of stroke, coronary 
heart disease (myocardial infarction, percutaneous coronary 
intervention, or coronary artery bypass grafting), chronic 
obstructive pulmonary disease, and neurodegenerative dis-
ease (dementia and parkinsonism) was assessed by interview 
and verified by reviewing medical records [14–17].
Statistical analyses
We used the independent samples t-test (for continuous vari-
ables with a normal distribution), the Wilcoxon signed-rank 
test (for continuous variables with a skewed distribution), 
or the Chi squared test (for categorical variables) to investi-
gate differences in characteristics between participants with 
pathology-confirmed diagnoses (certain cancer) and those 
with non pathology-confirmed diagnoses (probable and pos-
sible cancer). Furthermore, we compared cancer site spe-
cific percentages. An overview of the different ICD-10 codes 
used for categorisation into different cancer sites is presented 
in Supplementary Table 1.
Next, we explored a potential trend of pathological con-
firmation of cancer diagnoses over the years by plotting the 
number of incident pathology-confirmed and non pathology-
confirmed diagnoses per calendar year. We tested the asso-
ciation between year of diagnosis and source of diagnosis 
(with or without pathological confirmation) formally using 
logistic regression models. This analysis was performed for 
all cancer sites combined and for the five most frequently 
non pathology-confirmed cancer sites separately. We con-
structed two nested models: model I was unadjusted; model 
II was adjusted for age at diagnosis (continuous).
We used two different methods to estimate overall sur-
vival. First, time to event was defined as follow-up time 
starting from date of diagnosis until date of death or date 
of censoring (loss to follow-up or end of the study period 
[January 1st, 2014]), whichever came first). Second, dif-
ferences in overall survival between participants with and 
without pathological confirmation of the diagnosis were 
visualised by Kaplan–Meier curves and tested with a log-
rank test. We additionally computed standardised survival 
curves to remove the influence of different distributions in 
age at diagnosis and sex between the groups [18, 19].
Standardised survival curves were created using a pooled 
logistic regression model for death including the following 
covariates: time (years), time squared (years), pathological 
confirmation of the diagnosis, age at diagnosis (continuous), 
and sex. Interactions between time and time squared with 
source of diagnosis were added to the model to allow for a 
flexible estimation of the baseline hazard. After fitting the 
pooled logistic model, we estimated the probability of death 
if all participants with cancer had a pathology-confirmed 
diagnosis, and the probability of death if all participants with 
cancer had a non pathology-confirmed diagnosis at each 
time point. Subsequently we calculated the difference in sur-
vival probability at each time point by taking the cumulative 
product as with Kaplan–Meier method. Confidence intervals 
(CIs) were obtained by bootstrapping. In sensitivity analy-
ses, we repeated the analyses for cancer-specific survival and 
explored effect modification by median age, sex, education, 
and marital status.
Statistical analyses were performed using IBM SPSS Sta-
tistics Version 24.0 [20] and the packages ‘survival’ [21] and 
‘survminer’ [22] from R software Version 3.3.2.
Results
During a median (interquartile range) follow-up of 10.7 
(6.3–15.9) years, 2698 out of 14,024 participants were diag-
nosed with cancer. The majority had a pathology-confirmed 
diagnosis (n = 2382 [88.3%]). Of the participants with a non 
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pathology-confirmed diagnosis, 257 (9.5%) had a probable 
diagnosis and 59 (2.2%) had a possible diagnosis.
Characteristics of participants categorised into three 
groups, i.e., without cancer, with pathology-confirmed 
diagnosis, and with non pathology-confirmed diagnosis, 
are presented in Table 1. Participants with non pathology-
confirmed diagnoses were older at diagnosis compared to 
participants with pathology-confirmed diagnoses (median 
age of 83.2 vs. 74.2 years, P < .001). Furthermore, they were 
more often women (55.7% vs. 47.6%, P = .007), lived more 
often without a partner (37.3% vs. 25.1%, P < .001), and had 
lower educational levels (P = .002). Lastly, participants with 
non pathology-confirmed diagnoses had more often hyper-
tension (71.8% vs. 49.8%, P < .001) and more frequently a 
history of stroke (12.0% vs. 6.9%, P = .001), coronary heart 
disease (15.8% vs. 12.7%, P < .001), chronic obstructive pul-
monary disease (19.0% vs. 13.7%, P = .011), and neurode-
generative disease (30.4% vs. 14.8%, P < .001) at diagnosis 
than participants with pathology-confirmed diagnoses.
Most frequently diagnosed cancer sites that were 
non pathology-confirmed included central nervous sys-
tem (66.7% of all central nervous system cancers), 
Table 1  Characteristics of study population stratified by cancer diagnosis
Characteristics are measured at entry in the Rotterdam Study except for age at cancer diagnosis and comorbidities. Missing values are not 
imputed and therefore numbers do not always sum up to 100%
IQR interquartile range, N number of participants, SD standard deviation
*Two sided P values were calculated using the independent samples t-test (for continuous variables with a normal distribution), the Wilcoxon 
signed-rank test (for continuous variables with a skewed distribution), or the Chi squared test (for categorical variables) to investigate differences 
in characteristics between participants with pathology-confirmed diagnoses and participants with non pathology-confirmed diagnoses
Characteristic Participants without 
cancer (N = 11,326)
Participants with cancer (N = 2698)
Pathology-confirmed 
diagnosis (N = 2382)
Non pathology-confirmed 
diagnosis (N = 316)
P value*
Age, years, median (IQR) 62.4 (57.7–72.7) 65.0 (60.2–72.0) 72.0 (66.1–78.1) < .001
Sex, women, no. (%) 6912 (61.0) 1135 (47.6) 176 (55.7) .007
Marital status, no. (%) < .001
 Living with partner 7418 (65.5) 1723 (72.3) 181 (57.3)
 Living without partner 3036 (26.8) 597 (25.1) 118 (37.3)
Educational level, no. (%) .002
 Primary 2081 (18.4) 423 (17.8) 76 (24.1)
 Lower 4393 (38.8) 948 (39.8) 131 (41.5)
 Intermediate 2886 (25.5) 700 (29.4) 82 (25.9)
 Higher 1718 (15.2) 283 (11.9) 20 (6.3)
Body mass index, kg/m2, mean (SD) 26.9 (4.2) 26.7 (3.8) 26.3 (3.7) .137
Smoking, no. (%) .001
 Current 2313 (20.4) 608 (25.5) 90 (28.5)
 Former 4950 (43.7) 1106 (46.4) 109 (34.5)
 Never 3838 (33.9) 629 (26.4) 104 (32.9)
Alcohol use, no. (%) 7843 (69.2) 1683 (70.7) 188 (59.5) .287
Age at cancer diagnosis, years, no. (%)
 45–65 372 (15.6) 8 (2.5)
 65–75 897 (37.7) 42 (13.3)
 75–85 870 (36.5) 136 (43.0)
 > 85 243 (10.2) 130 (41.1)
Median (IQR) 74.2 (68.0–80.3) 83.2 (78.0–88.0) < .001
Comorbidities at cancer diagnosis, no. (%)
 Stroke 164 (6.9) 38 (12.0) .001
 Coronary heart disease 302 (12.7) 50 (15.8) < .001
 Hypertension 1186 (49.8) 227 (71.8) < .001
 Diabetes 324 (13.6) 37 (11.7) < .001
 Chronic obstructive pulmonary disease 326 (13.7) 60 (19.0) .011
 Neurodegenerative disease 353 (14.8) 44 (30.4) < .001
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hepato-pancreato-biliary (44.5%), unknown primary ori-
gin (31.2%), lung and mesothelioma (19.7%), and urinary 
tract (17.5%, Table 2). There was no statistically significant 
relation between pathological confirmation of these cancer 
sites with calendar year after adjustment for age at diagnosis, 
indicating that the number of participants with a pathology-
confirmed diagnosis did not increase or decrease during the 
study period (Supplementary Fig. 1 and Table 3).
Of the 2382 participants with a pathology-confirmed 
diagnosis, 1154 participants (48.4%) died from cancer 
and 455 participants (19.1%) died due to other causes, 
such as heart failure, dementia, and cardiac arrest. Among 
participants with non pathology-confirmed diagnoses, 231 
(73.1%) died from cancer, and 63 participants (19.9%) 
died from other causes. The overall survival of partici-
pants with non pathology-confirmed diagnoses was lower 
compared to participants with pathology-confirmed diag-
noses (P for log-rank test < 0.0001, Fig. 1). After adjusting 
for age at diagnosis and sex, the overall survival in partici-
pants with non pathology-confirmed diagnosis was 30.8% 
(95% CI 25.2%; 36.2%) lower 1 year after diagnosis com-
pared to participants with pathology-confirmed diagnoses 
(survival probability was 32.6% vs. 63.4%, respectively, 
Fig. 2). Two and five years after diagnosis, the difference 
in survival was 29.3% (95% CI 24.2%; 33.9%) and 22.5% 
(95% CI 17.7%; 26.4%), respectively. Cancer-specific 
survival probability was comparable to overall survival 
probability, with a lower cancer-specific survival in par-
ticipants with non pathology-confirmed diagnoses than in 
participants with pathology-confirmed diagnoses (37.2% 
vs. 67.4%, respectively, Supplementary Fig. 2). No sig-
nificant effect modification was observed across different 
strata of median age, sex, education, and marital status.
Table 2  Overview of number of 
pathological confirmations per 
cancer type
Numbers are displayed in total number (percentage per row)
Cancer site Pathology-confirmed 
diagnosis (N = 2382)
Non pathology-confirmed 
diagnosis (N = 316)
All cancer diag-
noses (N = 2698)
Head and neck 83 (94.3) 5 (5.7) 88
Oesophagus and gastric 140 (97.9) 3 (2.1) 143
Colorectal 397 (96.6) 14 (3.4) 411
Hepato-pancreato-biliary 81 (55.5) 65 (44.5) 146
Lung and mesothelioma 314 (80.3) 77 (19.7) 391
Bone and soft tissue 19 (90.5) 2 (9.5) 21
Breast 341 (96.6) 12 (3.4) 353
Female genital organs 112 (94.9) 6 (5.1) 118
Male genital organs 387 (95.6) 18 (4.4) 405
Unitary tract 165 (82.5) 35 (17.5) 200
Central nervous system 9 (33.3) 18 (66.7) 27
Haematological 188 (90.0) 21 (10.0) 209
Other 80 (88.9) 10 (11.1) 90
Unknown primary origin 66 (68.8) 30 (31.2) 96
Table 3  Association between calendar year of diagnosis and pathological confirmation of the cancer
CI confidence interval, N number of participants, OR odds ratio
Model I = unadjusted. Model II = adjusted for age at diagnosis (continuous)
Cancer site N pathology-con-
firmed diagnosis
N non pathology-con-
firmed diagnosis
Model I Model II
OR (95% CI) P OR (95% CI) P
All cancer sites 2382 316 1.01 (1.00–1.03) 0.13 1.01 (0.99–1.03) 0.27
Hepato-pancreato-biliary 81 65 0.97 (0.92–1.02) 0.25 0.95 (0.89–1.02) 0.15
Lung and mesothelioma 314 77 1.05 (1.01–1.09) 0.02 1.03 (0.99–1.08) 0.12
Unitary tract 165 35 0.96 (0.91–1.02) 0.21 0.96 (0.90–1.03) 0.26
Central nervous system 9 18 1.05 (0.93–1.19) 0.45 1.06 (0.94–1.21) 0.36
Unknown primary 66 30 1.06 (0.99–1.14) 0.10 1.05 (0.98–1.13) 0.17
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Discussion
In a large population-based cohort study, we showed that 
non pathology-confirmed diagnoses of cancer represent an 
additional ten percent of cancer diagnoses besides pathol-
ogy-confirmed diagnoses. Pathological confirmation of can-
cer was associated with multiple participant characteristics, 
comorbidities, cancer site, and survival. The proportion of 
participants with pathology-confirmed diagnoses did not 
change over time.
In line with previous studies investigating characteristics 
of patients with unstaged cancer [4–9], we found that par-
ticipants with a non pathology-confirmed diagnosis were on 
average older compared to those with a pathology-confirmed 
diagnosis. There are different reasons for this observation. 
First, older patients have more comorbidities that may be 
of greater health concern than a potential cancer diagno-
sis [23]. Therefore, the diagnostic cancer work-up may be 
partly omitted. Furthermore, older patients are sometimes 
more vulnerable, limiting the ability to obtain pathology 
material for diagnosis through invasive procedures, such as 
endoscopic retrograde cholangiopancreatography (ERCP) 
for pancreatic cancer. In addition, age and comorbidities are 
associated with potentially less intensive treatment assign-
ment including palliative radiotherapy and hormonal therapy 
[24, 25]. Although pathological confirmation of the cancer 
is often preferred, it may not always be mandatory for these 
treatment regimens [23, 26].
Lack of therapeutic consequences of pathological con-
firmation may explain why cancers with a poor survival in 
particular, such as cancer of central nervous system, hepato-
pancreato-biliary tract, and lung were often diagnosed 
without pathological confirmation. Cancers at these organ 
sites are often detected in a more advanced stage, limiting 
treatment options to palliative treatments. Furthermore, we 
found that participants with cancer of unknown primary 
Fig. 1  Kaplan–Meier curves for overall survival of participants with 
a pathology-confirmed diagnosis (blue) or a non pathology-confirmed 
diagnosis (yellow). Participants with a non pathology-confirmed 
diagnosis had significantly worse overall survival compared to those 
with a pathology-confirmed diagnosis (P of log-rank test < 0.0001). 
Participants were censored if they if they were lost to follow-up or at 
the end of the study period (January 1st, 2014), whichever came first
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origin often had no pathological confirmation, suggesting 
that these participants had metastasised disease and did not 
undergo further diagnostic testing [27]. Another explana-
tion for this finding is that cancers at these sites are less 
accessible for obtaining tumour tissue, in particular regard-
ing cancers of the central nervous system. Lastly, cancers in 
the urinary tract including renal cell carcinoma and prostate 
cancer were often non pathology-confirmed. These cancers 
are often diagnosed non-invasively with imaging modalities 
(renal cell carcinoma) or by the assessment of tumour mark-
ers (prostate cancer). Watchful waiting is increasingly being 
considered as an option for older, vulnerable patients with 
regard to prostate cancer [28], resulting in a lower number 
of pathology-confirmed diagnoses.
Interestingly, we showed that participants with a non 
pathology-confirmed diagnosis of cancer had worse overall 
and cancer-specific survival compared to participants with 
a pathology-confirmed diagnosis. Although the number of 
cancers with a poor survival was more frequently repre-
sented among non pathology-confirmed diagnoses, this dif-
ference in cancer type distribution cannot completely explain 
the observed difference in survival. Therefore, the difference 
in survival may indicate that pathological confirmation is 
more often omitted in patients with a ‘worse’ cancer prog-
nosis. In contrast, previous studies found a better survival in 
patients with unstaged cancer. For instance, unstaged colo-
rectal cancer was associated with higher survival compared 
to patients with distant-staged cancer [5]. Furthermore, non 
pathology-confirmed early stage lung cancer patients had 
a better cancer-specific survival compared to patients with 
a pathology-confirmed diagnosis, due to the occurrence of 
benign lung nodules among the diagnosed cancers with-
out pathological confirmation [29]. This misclassification 
of benign tumours may partly explain the discrepancy in 
survival between previous studies and the current study. 
Although we cannot exclude that we also classified benign 
tumours as non pathology-confirmed cancers, the number of 
misclassified tumours is expected to be low because of the 
persistent poor cancer-specific survival of participants with 
a non pathology-confirmed diagnosis.
We previously showed that cancer registries primar-
ily rely on pathology databases as signalling source of 
cancer diagnoses, resulting in under-registration of non 
pathology-confirmed diagnoses [30]. The findings of our 
current study indicate that under-registration of such can-
cers may result in underestimation of the cancer incidence, 
Fig. 2  Standardised survival curves of individuals with a pathology-
confirmed diagnosis (blue) or a non pathology-confirmed diagnosis 
(yellow). Dashed lines represent 95% confidence intervals. Survival 
curves are adjusted for age at diagnosis and sex. The risk difference 
of overall survival between participants with a non pathology-con-
firmed and a pathology-confirmed diagnosis is 30.8% after 1  year, 
29.3% after 2 years, and 22.5% after 5 years
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and in overestimation of cancer survival. Furthermore, non 
pathology-confirmed diagnoses were related to multiple 
characteristics including age, sex, smoking status, and 
education, and to cancer site. Most aetiological studies 
only include patients with a pathology-confirmed diagno-
sis, which may induce information bias and result in inac-
curate estimates of association [31]. For these reasons, our 
results suggest that registries and research studies should 
also include patients with non pathology-confirmed diag-
noses for potential sensitivity analyses.
The main strength of this study is the unique setting of 
the Rotterdam Study in which cancer registration relies 
on medical letters and medical records from the general 
practitioners in addition to signalling of diagnoses through 
the nationwide pathology database as well as linkage to 
the national cancer registry. This allowed us to investi-
gate also non pathology-confirmed diagnoses not regis-
tered through the pathology database. Furthermore, we 
estimated survival by computing standardised survival 
curves in addition to the unadjusted Kaplan–Meier curves. 
Unfortunately, we could not adjust these survival curves 
for frailty. Although the Rotterdam Study started to col-
lect data on frailty from 2009 onwards, including weight 
loss, physical activity, weakness, slowness, and fatigue to 
calculate the Fried frailty index [32], this was not available 
for the majority of the participants (< 20%), or—if avail-
able—was measured several years after cancer diagnosis. 
Another limitation is that the date of diagnosis is deter-
mined differently for non pathology-confirmed and pathol-
ogy-confirmed diagnoses. It is plausible that participants 
with non pathology-confirmed diagnoses were diagnosed 
sooner, resulting in a slightly longer cancer-specific sur-
vival. Lastly, we cannot rule out that non pathology-con-
firmed diagnoses are benign tumours. However, we clas-
sified cancers based on all the available information from 
medical letters and medical records, limiting the number 
of false positive diagnoses. In addition, we showed that 
participants with non pathology-confirmed diagnoses had 
worse cancer-specific survival persistent over time, sug-
gesting that these cancers were malignant.
In conclusion, we show that purely non pathology-con-
firmed diagnoses represent ten percent of the total number 
of diagnosed cancers, besides pathology-confirmed diag-
noses. Pathological confirmation is associated with several 
characteristics and with worse overall and cancer-specific 
survival. Our findings suggest that missing data or exclu-
sion of non pathology-confirmed diagnoses may result in 
underestimation of the true cancer incidence, overesti-
mation of survival, and potentially may bias aetiological 
research findings.
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